Veloxis Pharmaceuticals announced that LCP-Tacro successfully demonstrated non-inferiority compared to tacrolimus (Prograf®; Astellas Pharma) in its Phase III clinical trial, Study 3002.
The Phase III randomized, double-blind and double-dummy study in 543 de novo kidney transplant recipients, with Prograf as the comparator, met its primary efficacy and primary safety endpoints.
The study was conducted under a Special Protocol Agreement with the FDA and the results are considered pivotal for the planned U.S. regulatory filing expected to occur in the second half of 2013.
"The results observed in this clinical trial suggest that new kidney transplant patients can begin with a regimen of once-daily LCP-Tacro™ rather than twice-daily as required with current tacrolimus products, without compromising efficacy and tolerability," said Dr. Suphamai Bunnapradist, M.D., Professor of Medicine and Director of Kidney Transplant Research at the Ronald Reagan Medical Center and David Geffen School of Medicine at UCLA, California, USA. "This is important because once-daily dosing should be beneficial for kidney transplant patients who are on life-long complex therapy."
LCP-Tacro demonstrated non-inferiority to Prograf in preventing kidney transplant rejection, including in the early post-transplant period
The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection or BPAR, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of LCP-Tacro compared to Prograf.
The treatment failure rate for LCP-Tacro was 18.3% compared to 19.6% for Prograf, well within the 10% pre-specified non-inferiority margin.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Today's Global Warming Is Nothing Special
- Curiosity Detects Spike In Methane, And Other Organic Molecules, On Mars
- There Was No 'Paleo Diet' - Ancient People Ate What They Had
- Worldwide, Life Expectancy Has Gone Up Over 6 Years Since 1990
- New Limits On VY Production From CDF: Good, But Also Disappointing
- Time To Stop Thinking Of Video Games As Just 'Software'
- Is Big Data Taking Over The Fashion Industry?
- "old news ..."
- "This research has virtually no bearing on the problem of AGW. Survival of early life is not the..."
- "I would have also checked vitamin D status. UVA breaks down vitamin A..."
- "Every day it is becoming harder to subscribe to the 'Fanaticism Of The Apocalypse' as it is applied..."
- "Curious conversation tactic. By the warming in the 1930s I guess you mean the small part of the..."
- Report: Clearing rainforests distorts wind and water, packs climate wallop beyond carbon
- Electron spin could be the key to high-temperature superconductivity
- Study shows epinephrine auto-injectors and asthma inhalers used incorrectly
- Moms of food-allergic kids need dietician's support
- How does prostate cancer form?